Cellular and molecular mechanisms underlying bone marrow and liver fibrosis: A review

European Cytokine Network

Volumn 19, Issue 2, 2008, Pages 69-80

  Bousse Kerdiles, Marie Caroline Le ^a,b   Martyre, Marie Claire ^a,b   Samson, Michel ^c  

^a HÔPITAL PAUL BROUSSE   (France)

^b UNIVERSITÉ PARIS SACLAY   (France)

^c UNIVERSITÉ DE RENNES 1   (France)

Author keywords

Extracellular matrix (ECM) components; Fibroblasts; TGF beta

Indexed keywords

ANGIOGENIC FACTOR; BORTEZOMIB; CYTOKINE; GROWTH FACTOR; INTERLEUKIN 13; JANUS KINASE 2; PROTEINASE; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA RECEPTOR; SIGNAL PEPTIDE;

CELL ACTIVITY; CELL INFILTRATION; CELL PROLIFERATION; CELL TYPE; CONNECTIVE TISSUE; EXTRACELLULAR MATRIX; FIBROGENESIS; HEMATOPOIETIC CELL; HISTOPATHOLOGY; HUMAN; LEUKOCYTE; LIPID PEROXIDATION; LIVER FIBROSIS; LIVER HISTOLOGY; MEGAKARYOPOIESIS; MOLECULAR MECHANICS; MYELOFIBROSIS; MYOFIBROBLAST; NONHUMAN; PHENOTYPE; PROTEIN DEGRADATION; PROTEIN SYNTHESIS; REVIEW; TISSUE INJURY; ANIMAL; BIOLOGICAL MODEL; BONE MARROW; FIBROBLAST; LIVER CIRRHOSIS; METABOLISM; MOUSE; PATHOLOGY;

ANIMALIA;

ANIMALS; BONE MARROW; CYTOKINES; EXTRACELLULAR MATRIX; FIBROBLASTS; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; LIVER CIRRHOSIS; MICE; MODELS, BIOLOGICAL; MYELOFIBROSIS; TRANSFORMING GROWTH FACTOR BETA;

EID: 55749093276     PISSN: 11485493     EISSN: None     Source Type: Journal    
DOI: 10.1684/ecn.2008.2027     Document Type: Review

References (100)

1. Reilly JT. Idiopathic myelofibrosis: pathogenesis, natural history and management. Blood Rev 1997; 11: 233.
2. Tefferi A. Pathogenesis of myelofibrosis with myeloid metaplasia. J Clin Oncol 2005; 23: 8520.
3. Thiele J, Kvasnicka HM. Myelofibrosis in chronic myeloproliferative disorders dynamics and clinical impact. Histol Histopathol2006; 21: 1367.
4. Mesa RA, Hanson CA, Rajkumar SV, Schroeder G, Tefferi A. Evaluation and clinical correlations of bone marrow angiogenesis in myelofibrosis with myeloid metaplasia. Blood 2000; 96: 3374.
5. Bock O, Neuse J, Hussein K, Brakensiek K, Buesche G, Buhr T, Wiese B, Kreipe H. Aberrant collagenase expression in chronic idiopathic myelofibrosis is related to the stage of disease but not to the JAK2 mutation status. Am J Pathol 2006; 169: 471.
6. Hasselbalch HC. Idiopathic myelofibrosis. Clinical aspects and studies on extracellular matrix metabolism. Dan Med Bull 1993; 40: 39.
7. Thiele J, Kvasnicka HM, Facchetti F, Franco V, van der Walt J, Orazi A. European consensus on grading bone marrow fibrosis and assessment of cellularity. Haematologica 2005; 90: 1128.
8. Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology 1996; 24: 289.
9. Knodell RG, Ishak KG, Black WC, et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1981; 1:431.
10. Cappio FC, Vigliani R, Novarino A, Camussi G, Campana D, GavostoF. Idiopathic myelofibrosis: a possible role for immune complexes in the pathogenesis of bone marrow fibrosis. Br J Haematol 1981; 49: 17.
11. Terui T, Niitsu Y, Mahara K, et al. The production of transforming growth factor-beta in acute megakaryoblastic leukemia and its possible implications in myelofibrosis. Blood 1990; 75: 1540.
12. Gruber G, Schwarzmeier JD, Shehata M, Hilgarth M, Berger R. Basic fibroblast growth factor is expressed by CD19/CD11c positive cells in hairy cell leukemia. Blood 1999; 94: 1077.
13. Martyre MC. TGF-beta and megakaryocytes in the pathogenesis of myelofibrosis in myeloproliferative disorders. Leuk Lymphoma 1995; 20: 39.
14. Castro-Malaspina H, Jhanwar SC. Properties of myelofibrosis derived fibroblasts. Prog Clin Biol Res 1984; 154: 307.
15. Martyre MC, Romquin N, Le Bousse-Kerdiles MC, et al. Trans forming growth factor-beta and megakaryocytes in the pathogen esis of idiopathic myelofibrosis. Br J Haematol 1994; 88: 9.
16. Rameshwar P, Denny TN, Stein D, Gascon P. Monocyte adhesionin patients with bone marrow fibrosis is required for the production of fibrogenic cytokines. Potential role for interleukin-1 and TGF beta. J Immunol 1994; 153: 2819.
17. Rameshwar P, Narayanan R, Qian J, Denny TN, Colon C, Gascon P. NF-kappa B as a central mediator in the induction of TGF beta in monocytes from patients with idiopathic myelofibrosis: an inflammatory response beyond the realm of homeostasis. J Immunol 2000; 165: 2271.
18. Frey BM, Rafii S, Teterson M, Eaton D, Crystal RG, Moore MA. Adenovector-mediated expression of human thrombopoietinc DNA in immune-compromised mice: insights into the patho physiology of osteomyelofibrosis. J Immunol 1998; 160: 691.
19. Wagner-Ballon O, Chagraoui H, Prina E, et al. Monocyte/ macrophage dysfunctions do not impair the promotion of myelofi brosis by high levels of thrombopoietin. J Immunol 2006; 176: 6425.
20. Komura E, Tonetti C, Penard-Lacronique V, et al. Role for the nuclear factor kappaB pathway in transforming growth factor beta1 production in idiopathic myelofibrosis: possible relationship with FK506 binding protein 51 overexpression. Cancer Res 2005;65: 3281.
21. Bataller R, Brenner DA. Liver fibrosis. J Clin Invest 2005; 115: 209-18.
22. Steiling H, Muhlbauer M, Bataille F, Scholmerich J, Werner S, Hellerbrand C. Activated hepatic stellate cells express keratinocyte growth factor in chronic liver disease. Am J Pathol 2004; 165: 1233.
23. Burt AD, Oakley CL. Cellular and molecular aspects of hepatic fibrosis. J Pathol 1993; 170: 105.
24. Shiraishi T, Morimoto S, Koh E, Fukuo K, Ogihara T. Increased release of platelet-derived growth factor from platelets in chronic liver disease. Eur J Clin Chem Clin Biochem 1994; 32: 5.
25. Bock O, Loch G, Busche G, von Wasielewski R, Schlue J Kreipe H. Aberrant expression of platelet-derived growth factor (PDGF) and PDGF receptor-alpha is associated with advanced bone marrow fibrosis in idiopathic myelofibrosis. Haematologica 2005; 90: 133.
26. Brouty-Boye D. Developmental biology of fibroblasts and neoplastic disease. Prog Mol Subcell Biol 2005; 40: 55.
27. Shehata M, Schwarzmeier JD, Hilgarth M, Hubmann R, Duechler M, Gisslinger H. TGF-beta1 induces bone marrow reticulin fibrosis in hairy cell leukemia. J Clin Invest 2004; 113: 676.
28. Wynn TA. Common and unique mechanisms regulate fibrosis in various fibroproliferative diseases. J Clin Invest 2007; 117: 524.
29. Wynn TA. Fibrotic disease and the T(H)1/T(H)2 paradigm. Nat Rev Immunol 2004; 4: 583.
30. Bucala R, Spiegel LA, Chesney J, Hogan M, Cerami A. Circulating fibrocytes define a new leukocyte subpopulation that mediates tissue repair. Mol Med1994; 1: 71-81.
31. Quan TE, Cowper SE, Bucala R. The role of circulating fibrocytesin fibrosis. Curr Rheumatol Rep 2006; 8: 145.
32. Safadi R, Friedman SL. Hepatic fibrosis role of hepatic stellate cell activation. Med Gen Med 2002; 4: 27.
33. Friedman SL. Stellate cells: a moving target in hepatic fibrogenesis. Hepatology 2004; 40: 1041.
34. Friedman SL. Hepatic stellate cells: protean, multifunctional and enigmatic cells of the liver. Physiol Rev 2008; 88: 125.
35. Buschle M, Janssen JW, Drexler H, Lyons J, Anger B, Bartram CR. Evidence for pluripotent stem cell origin of idiopathic myelofibrosis: clonal analysis of a case characterized by a N-ras gene mutation. Leukemia 1988; 2: 658.
36. Bilhou-Nabera C, Brigaudeau C, Clay D, et al. Does cytogenetic mosaicism in CD34+CD38low cells reflect the persistence of normal primitive hematopoietic progenitors in myeloid metaplasia with myelofibrosis? Blood 2003; 102: 1551.
37. Wang JC, Lang HD, Lichter S, Weinstein M, Benn P. Cytogenetic studies of bone marrow fibroblasts cultured from patients with myelofibrosis and myeloid metaplasia. Br J Haematol 1992; 80: 184.
38. Castro-Malaspina H. Pathogenesis of myelofibrosis: role of ineffective megakaryopoiesis and megakaryocyte components. Prog Clin Biol Res 1984; 154: 427.
39. Massague J. The transforming growth factor-beta family. Annu Rev Cell Biol 1990; 6: 597.
40. Verrecchia F, Mauviel A. Transforming growth factor-beta signaling through the Smad pathway: role in extracellular matrix gene expression and regulation. J Invest Dermatol 2002; 118: 211.
41. Border WA, Noble NA. Transforming growth factor beta in tissue fibrosis. N Engl J Med 1994; 331: 1286.
42. Reilly JT, Barnett D, Dolan G, Forrest P, Eastham J, Smith A.Characterization of an acute micromegakaryocytic leukaemia: evidence for the pathogenesis of myelofibrosis. Br J Haematol 1993;83: 58.
43. Martyre MC, Magdelenat H, Bryckaert MC, Laine-Bidron C, Calvo F. Increased intraplatelet levels of platelet-derived growth factor and transforming growth factor-beta in patients with myelofibrosis with myeloid metaplasia. Br J Haematol 1991; 77: 80.
44. Zauli G, Visani G, Catani L, Vianelli N, Gugliotta L, Capitani S.Reduced responsiveness of bone marrow megakaryocyte progenitors to platelet-derived transforming growth factor beta 1, producedin normal amount, in patients with essential thrombocythaemia. Br J Haematol 1993; 83: 14.
45. Le Bousse-Kerdiles MC, Chevillard S, Charpentier A, et al. Differential expression of transforming growth factor-beta, basic fibroblast growth factor, and their receptors in CD34+ hematopoietic progenitor cells from patients with myelofibrosis and myeloid metaplasia. Blood 1996; 88: 4534.
46. Martyre MC, Le Bousse-Kerdiles MC, Romquin N, et al. Elevated levels of basic fibroblast growth factor in megakaryocytes and platelets from patients with idiopathic myelofibrosis. Br J Haema tol 1997; 97: 441.
47. Dalley A, Smith JM, Reilly JT, Neil SM. Investigation of calmodulin and basic fibroblast growth factor (bFGF) in idiopathic myelofibrosis: evidence for a role of extracellular calmodulin in fibroblast proliferation. Br J Haematol 1996; 93: 856.
48. Di Raimondo F, Azzaro MP, Palumbo GA, et al. Elevated vascular endothelial growth factor (VEGF) serum levels in idiopathic my elofibrosis. Leukemia 2001; 15: 976-80.
49. Davis BH, Rapp UR, Davidson NO. Retinoic acid and transforming growth factor beta differentially inhibit platelet-derived growth-factor-induced Ito-cell activation. Biochem J 1991; 278(Pt1): 43.
50. Svegliati-Baroni G, Saccomanno S, van Goor H, Jansen P, Benedetti A, Moshage H. Involvement of reactive oxygen species and nitric oxide radicals in activation and proliferation of rat hepatic stellate cells. Liver 2001; 21: 1.
51. Schmitt A, Jouault H, Guichard J, Wendling F, Drouin A,Cramer EM. Pathologic interaction between megakaryocytes and polymorphonuclear leukocytes in myelofibrosis. Blood 2000; 96: 1342.
52. Smadja-Joffe F, Legras S, Girard N, et al. CD44 and hyaluronan binding by human myeloid cells. Leuk Lymphoma 1996; 21: 407;(color plates following 528).
53. Le Bousse-Kerdiles MC, Martyre MC. Myelofibrosis: pathogenesis of myelofibrosis with myeloid metaplasia. French INSERM Research Network on Myelofibrosis with Myeloid Metaplasia. Springer Semin Immunopathol 1999; 21: 491.
54. Zhu H, Mitsuhashi N, Klein A, et al. The role of the hyaluronan receptor CD44 in mesenchymal stem cell migration in the extra cellular matrix. Stem Cells 2006; 24: 928.
55. De Bleser PJ, Niki T, Rogiers V, Geerts A. Transforming growth factor-beta gene expression in normal and fibrotic rat liver. J Hepatol 1997; 26: 886.
56. Nakamura T, Sakata R, Ueno T, Sata M, Ueno H. Inhibition of transforming growth factor beta prevents progression of liver fibrosis and enhances hepatocyte regeneration in dimethylnitrosamine treated rats. Hepatology 2000; 32: 247.
57. Imamura M, Ogawa T, Sasaguri Y, Chayama K, Ueno H. Suppression of macrophage infiltration inhibits activation of hepatic stellate cells and liver fibrogenesis in rats. Gastroenterology 2005;128: 138.
58. Hata J, Ikeda E, Uno H, Asano S. Expression of hepatocyte growth factor mRNA in rat liver cirrhosis induced by N-nitrosodimethylamine as evidenced by in situ RT-PCR. J His tochem Cytochem 2002; 50: 1461.
59. Luckey SW, Petersen DR. Activation of Kupffer cells during the course of carbon tetrachloride-induced liver injury and fibrosis in rats. Exp Mol Pathol 2001; 71: 226.
60. Roland CR, Goss JA, Mangino MJ, Hafenrichter D, Flye MW. Autoregulation by eicosanoids of human Kupffer cell secretory products. A study of interleukin-1, interleukin-6, tumor necrosis factor-alpha, transforming growth factor-beta, and nitric oxide. Ann Surg 1994; 219: 389.
61. Xidakis C, Ljumovic D, Manousou P, Notas G, Valatas V, Kolios G, Kouroumalis E. Production of pro- and anti-fibrotic agents by rat Kupffer cells; the effect of octreotide. Dig Dis Sci 2005; 50: 935.
62. Seki E, De Minicis S, Osterreicher CH, Kluwe J, Osawa Y, Brenner DA, Schwabe RF. TLR4 enhances TGF-beta signaling and hepatic fibrosis. Nat Med 2007; 13:1324.
63. Crawford SE, StellmachV, Murphy-Ullrich JE, Ribeiro SM,Lawler J Hynes RO Boivin GP Bouck N. Thrombospondin-1 is a major activator of TGF-beta1 in vivo. Cell 1998; 93: 1159.
64. Yang Z, Mu Z, Dabovic B, Jurukovski V, Yu D, Sung J, Xiong X, Munger JS. Absence of integrin-mediated TGFbeta1 activation invivo recapitulates the phenotype of TGFbeta1-null mice. J Cell Biol 2007; 176: 787.
65. Munger JS, Huang X, Kawakatsu H, et al. The integrin alpha vbeta 6 binds and activates latent TGF beta 1: a mechanism for regulating pulmonary inflammation and fibrosis. Cell 1999; 96:319.
66. Wang JC, Novetsky A, Chen C, Novetsky AD. Plasma matrix met alloproteinase and tissue inhibitor of metalloproteinase in patients with agnogenic myeloid metaplasia or idiopathic primary myelofi brosis. Br J Haematol 2002; 119: 709.
67. Wang JC. Importance of plasma matrix metalloproteinases (MMP) and tissue inhibitors of metalloproteinase (TIMP) in development of fibrosis in agnogenic myeloid metaplasia. Leuk Lymphoma 2005; 46: 1261.
68. James C, Ugo V, Le Couedic JP, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 2005; 434: 1144.
69. Baxter EJ, Scott LM, Campbell PJ, et al. Acquired mutation ofthe tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 2005; 365: 1054.
70. Kralovics R, Passamonti F, Buser AS, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. NEngl J Med 2005; 352: 1779.
71. Levine RL, Wadleigh M, Cools J, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thromb ocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 2005; 7: 387.
72. Iredale JP. Tissue inhibitors of metalloproteinases in liver fibrosis. Int J Biochem Cell Biol 1997; 29: 43.
73. Benyon RC, Arthur MJ. Extracellular matrix degradation and the role of hepatic stellate cells. Semin Liver Dis 2001; 21: 373.
74. Le Bousse-Kerdiles MC, Smadja-Joffe F, Klein B, Caillou B, Jasmin C. Study of a virus-induced myeloproliferative syndrome associated with tumor formation in mice. Eur J Cancer 1980; 16: 43.
75. Le Bousse-Kerdiles MC, Souyri M, Smadja-Joffe F, Praloran V,Jasmin C, Ziltener HJ. Enhanced hematopoietic growth factor production in an experimental myeloproliferative syndrome. Blood 1992; 79: 3179.
76. Villeval JL, Cohen-Solal K, Tulliez M, et al. High thrombopoietin production by hematopoietic cells induces a fatal myeloprolifera tive syndrome in mice. Blood 1997; 90: 4369.
77. Yan XQ, Lacey D, Hill D, Chen Y, Fletcher F, Hawley RG, Mc Niece IK. A model of myelofibrosis and osteosclerosis in mice induced by overexpressing thrombopoietin (mpl ligand): reversal of disease by bone marrow transplantation. Blood 1996; 88: 402.
78. Vannucchi AM, Bianchi L, Cellai C, et al. Development of my elofibrosis in mice genetically impaired for GATA-1 expression (GATA-1(low)mice). Blood 2002; 100: 1123.
79. Vannucchi AM, Bianchi L, Paoletti F, et al. A pathobiologic path way linking thrombopoietin, GATA-1, and TGF-beta1 in the development of myelofibrosis. Blood 2005; 105: 3493.
80. Chagraoui H, Komura E, Tulliez M, Giraudier S, Vainchenker W, Wendling F. Prominent role of TGF-beta 1 in thrombopoietin induced myelofibrosis in mice. Blood 2002; 100: 3495.
81. Wernig G, Mercher T, Okabe R, Levine RL, Lee BH, Gilliland DG. Expression of Jak2V617F causes a polycythemia vera-like disease with associated myelofibrosis in a murine bone marrow transplant model. Blood 2006; 107: 4274.
82. Lacout C, Pisani DF, Tulliez M, Gachelin FM, Vainchenker W,Villeval JL. JAK2V617F expression in murine hematopoietic cells leads to MPD mimicking human PV with secondary myelofibrosis. Blood 2006; 108: 1652.
83. Tiedt R, Hao-Shen H, Sobas MA, Looser R, Dirnhofer S, Schwaller J, Skoda RC. Ratioofmutant JAK2-V617Ftowild-type Jak2 determines the MPD phenotypes in transgenic mice. Blood 2008; 111: 3931.
84. Hellerbrand C, Stefanovic B, Giordano F, Burchardt ER, Brenner DA. The role of TGFbeta1 in initiating hepatic stellate cell activation in vivo. J Hepatol 1999; 30: 77.
85. Xing S, Wanting TH, Zhao W, et al. Transgenic expression of JAK2V617F causes myeloproliferative disorders in mice. Blood 2008; 111: 5109-17.
86. George J, Roulot D, Koteliansky VE, Bissell DM. In vivo inhibition of rat stellate cell activation by soluble transforming growth factor beta type II receptor: a potential new therapy for hepatic fibrosis. Proc Natl Acad Sci USA 1999; 96: 12719.
87. Qi Z, Atsuchi N, Ooshima A, Takeshita A, Ueno H. Blockade of type beta transforming growth factor signaling prevents liver fibrosis and dysfunction in the rat. Proc Natl Acad Sci USA 1999; 96:2345.
88. Cheever AW, Williams ME, Wynn TA, et al. Anti-IL-4 treatment of Schistosoma mansoni-infected mice inhibits development of T cells and non-B, non-T cells expressing Th2 cytokines while decreasing egg-induced hepatic fibrosis. J Immunol 1994; 153: 753.
89. Chiaramonte MG, Cheever AW, Malley JD, Donaldson DD, Wynn TA. Studies of murine schistosomiasis reveal interleukin-13 blockade as a treatment for established and progressive liver fibrosis. Hepatology 2001; 34: 273.
90. Chiaramonte MG, Donaldson DD, Cheever AW, Wynn TA. An IL-13 inhibitor blocks the development of hepatic fibrosis during a T-helper type 2-dominated inflammatory response. J Clin Invest 1999; 104: 777.
91. Fallon PG, Richardson EJ, McKenzie GJ, McKenzie AN. Schisto some infection of transgenic mice defines distinct and contrasting pathogenic roles for IL-4 and IL-13: IL-13 is a profibrotic agent. J Immunol 2000; 164: 2585.
92. Kaviratne M, Hesse M, Leusink M, et al. IL-13 activates a mechanism of tissue fibrosis that is completely TGF-beta independent. J Immunol 2004; 173: 4020.
93. Gastinne T, Vigant F, Lavenu-Bombled C, et al. Adenoviral mediated TGF-beta1 inhibition in a mouse model of myelofibrosis inhibit bone marrow fibrosis development. Exp Hematol 2007; 35:64.
94. Wagner-Ballon O, Pisani DF, Gastinne T, et al. Proteasome inhibitor bortezomib impairs both myelofibrosis and osteosclerosis induced by high thrombopoietin levels in mice. Blood 2007; 110:345.
95. Pardanani A. JAK2 inhibitor therapy in myeloproliferative disorders: rationale, preclinical studies and ongoing clinical trials. Leukemia 2008; 22: 23.
96. Deeg HJ, Gooley TA, Flowers ME, et al. Allogeneic hematopoietic stem cell transplantation for myelofibrosis. Blood 2003; 102:3912.
97. Higashiyama R, Inagaki Y, Hong YY, et al. Bone marrow-derived cells express matrix metalloproteinases and contribute to regression of liver fibrosis in mice. Hepatology 2007; 45: 213.
98. Inagaki Y, Higashiyama R, Okazaki I. Treatment strategy for liver fibrosis through recruitment and differentiation of bone marrow stem/progenitor cells. Hepatol Res 2007; 37: 991.
99. Lotersztajn S, Julien B, Teixeira-Clerc F, Grenard P, Mallat A.Hepatic fibrosis: molecular mechanisms and drug targets. Annu Rev Pharmacol Toxicol 2005; 45: 605.
100. Breitkopf K, Haas S, Wiercinska E, Singer MV, Dooley S. Anti TGF-beta strategies for the treatment of chronic liver disease. Alcohol Clin Exp Res 2005; 29: 121S.